VC Firm SR One Closes $600M Fund to Build ‘Elite Biotechnology Companies’
SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.
Vying to best bigger rivals in Parkinson’s, Neuron23 nabs $100M to reach clinic
Neuron23 is developing drugs that treat neurological conditions by penetrating the blood-brain barrier to reach disease targets in the central nervous system. The biotech's lead program is a Parkinson’s disease drug candidate with features that could distinguish it from rival compounds that are aiming for the same target.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.
AI firm BenchSci raises $50M for tech that takes waste out of preclinical research
BenchSci’s technology uses artificial intelligence to make drug R&D faster and more efficient. Big pharmaceutical companies and clinical-stage biotechs are current users of the software, and BenchSci said it will use its new funding to expand the technology.
Section 32’s newest partner shares investment approach going into fund 3
Steve Kafka, who joined Section 32 as a managing partner last fall, shared more about how the fund approaches investing across technology and healthcare. The company is currently raising $350 million for its third fund.
Funding roundup: At-home medical exams and a Parkinson’s treatment
Numerous companies with remote-monitoring and telehealth services closed funding rounds this week. Tyto Care, which gives users the tools to conduct an at-home medical exam with their doctor, raised $50 million. On the biotech side, Aspen Neuroscience, which is developing a new treatment for Parkinson's disease, raised $70 million.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Funding roundup: Pandion Therapeutics raises $80M for autoimmune disease treatment
Despite continued economic impacts from the Covid-19 pandemic, biotechnology companies and VC firms raised significant amounts of funding this week. For example, Massachusetts-based Pandion Therapeutics closed $80 million in funding to develop a therapeutic designed to treat autoimmune diseases.
How are healthcare VCs in every sector handling Covid-19?
Venture capital firms are making fewer investments as the Covid-19 pandemic surges in the U.S. But many still say they are still open for business.
Healthcare startups saw more deals, fewer dollars in 2019
Healthcare startups saw smaller amounts of investment after a record-breaking 2018, according to a report from Silicon Valley Bank. Despite the dip in funding, 2019 saw more deals overall, led by increased investment into healthcare technology companies.
uBiome, once a promising microbiome startup, files for bankruptcy
A mere five months after an FBI raid, the San Francisco startup, once valued at $600 million, has filed for bankruptcy. It will continue to offer its microbiome test while also looking for a buyer.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Kite Pharma founder’s venture capital firm closes new $600M fund
The new fund, announced Thursday by Arie Belldegrun's Vida Ventures, brings the total amount of money raised to approximately $1 billion.
Medicxi closes fund worth nearly $449 million, aims for investments in platforms, pipelines
While it trails its U.S. counterpart, Europe's life science sector has seen an increase in interest from investors lately. A report released Thursday by Silicon Valley Bank indicates growing investment in European biopharma and diagnostics.
RA Capital Management closes $308M venture capital fund
The firm said the new round increased its private deal capacity to nearly $1 billion and total assets under management to around $2.5 billion.
Scott Gottlieb returns to NEA – this time with some valuable regulatory experience under his belt
Gottlieb previously worked at NEA from 2007 to 2017, when he was appointed as commissioner of the FDA. He stepped down from that role in March, also returning to another previous employer, the American Enterprise Institute.
Despite Brexit anxiety, VC investment in UK biotech surges by more than $60M
A report, by the UK Bioindustry Association, found that venture capital investment in UK biotech companies rose from $178 million in first quarter 2018 to $240 million in first quarter 2019.